Study of the Safety and Tolerability of P 321 Ophthalmic Solution in Subjects With Dry Eye Disease

NCT ID: NCT02242032

Last Updated: 2015-05-04

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 53 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-07-31
• Study Completion Date: 2015-03-31

Brief Summary

The purpose of this study is to assess the safety and tolerability of P-321 Ophthalmic Solution in subjects with mild to moderate dry eye disease.

Detailed Description

This is a single-center, dose escalation, randomized, double-masked, placebo-controlled, Phase 1/2a trial designed to evaluate the safety and tolerability of P-321 Ophthalmic Solution in subjects with mild to moderate dry eye for up to 4-weeks of treatment and up to 8 scheduled in clinic visits. This study will conduct a consecutive dose escalation of the following concentrations of P-321 Ophthalmic Solution given two times a day via ocular instillation: 0.0005% (Cohort 1), 0.0015% (Cohort 2), 0.005% (Cohort 3), and 0.01% (Cohort 4). Up to 48 subjects will be enrolled in four consecutive cohorts. Subjects will be randomized to P-321 Ophthalmic Solution or placebo in a 3:1 ratio.

Safety and tolerability assessments, drug plasma concentrations and drug urine concentrations will be evaluated throughout the study in all cohorts.

Conditions

Dry Eye Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

P-321

P-321 Ophthalmic Solution

Group Type: EXPERIMENTAL

P-321 Ophthalmic Solution

Intervention Type: DRUG

P-321 Ophthalmic Solution Placebo

P-321 Ophthalmic Solution Placebo

Group Type: PLACEBO_COMPARATOR

P-321 Ophthalmic Solution placebo

Intervention Type: DRUG

Placebo to match P-321 Ophthalmic Solution

Interventions

P-321 Ophthalmic Solution

Intervention Type: DRUG

P-321 Ophthalmic Solution placebo

Placebo to match P-321 Ophthalmic Solution

Intervention Type: DRUG

Other Intervention Names

P-321; placebo

Eligibility Criteria

Inclusion Criteria

• Individuals of both genders and any race will be eligible for study participation if they:

1. Provide written informed consent.

2. Are 18 - 80 years of age.

3. Corneal fluorescein staining score ≥2/15 on the NEI/Industry scale

4. Conjunctival lissamine staining score of ≥ 2/18 on the NEI/Industry scale

5. Schirmer <10mm/5min

6. Are willing and able to follow instructions and can be present for the required study visits for the duration of the study.

7. Female patients of child bearing potential must have a negative urine pregnancy test at Screening and agree to use a medically acceptable form of birth control. Male subjects who are sexually active must be willing to use highly effective contraception (i.e., less than 1% failure rate) during heterosexual intercourse from Day 1 through completion of the study.

8. Have a history of Dry Eye Disease in both eyes supported by a previous clinical diagnosis or have a self-reported history of subjective complaints for at least 4 months prior to Screening, low tear volume, and ocular staining.

9. Have documented history of topical lubricants at least daily or the desire to use topical lubricants in the past 4 months.

10. Have normal lid anatomy

Exclusion Criteria

• Individuals are not eligible for study participation if:

1. Have anterior segment eye disease except primary dry eye.

2. Patients with an identifiable or suspected secondary dry eye, i.e., a documented or likely systemic, ocular, pharmacologic, post-traumatic, post-surgical, or external cause for dry eye symptoms or ocular surface staining.

3. Patients with current punctal plugs, punctal occlusion, or history of nasolacrimal duct obstruction are excluded.

4. Have a history of glaucoma or intraocular pressure (IOP) > 25 mmHg at the Screening Visit (Visit 1) or a history of elevated IOP within the past year prior to Visit 1

5. Contact lenses wear in the previous 30 days or during the Treatment Phase of the study.

6. Use of lid scrubs (including baby shampoos)

7. Known hypersensitivity to the study investigational medicinal product, or formulation excipients, including amiloride or related drugs or allergies to the components of the study drug.

8. Any significant chronic illness that, in the opinion of the Principal Investigator (PI), could interfere with the study parameters.

9. Use of any investigational product or device within 30 days prior to the Screening Visit or during the study.

10. Those unable in the opinion of the PI to comply fully with the study requirements or complete the study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Parion Sciences

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Kenneth Sall, MD

Role: PRINCIPAL_INVESTIGATOR

Sall Research Medical Center

Locations

Sall Research Medical Center

Artesia, California, United States

Countries

United States

Other Identifiers

P-321-101

Identifier Type: -

Identifier Source: org_study_id